Arcus biosciences stock

SVP, Technology & Quantitative Biology. Dr. You

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and …Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, ... 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock.Currently, Arcus Biosciences has an average volume of 1.19M. Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.

Did you know?

Dec 24, 2022 · HAYWARD, Calif., December 24, 2022 -- ( BUSINESS WIRE )--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today ... Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript. Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Arcus Biosciences, Inc. (NYSE: RCUS) was in 27 hedge funds' portfolios at the end of March. The all time high for this statistic is 31. RCUS has experienced a decrease in enthusiasm from smart ...Arcus Biosciences Inc. RCUS (U.S.: NYSE) Overview News Arcus Biosciences Inc. No significant news for in the past two years. Key Stock Data Shares Sold Short 6.92 M Change from Last 0.55%...How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding.Dec 1, 2023Evasões 7 vinhos de casta jaen do Dão que vale a pena experimentar Evasões Lugar referencial de todo o Dão moderno, este jaen tem tudo o que é preciso para perceber a casta. Atenção, está praticamente esgotado. Classificação Evasões: 17,5. Preço: 10 euros. Quinta-das-Maias-Jaen. Quinta das Maias Jaen DOC Dão tinto 2013 ...View the latest Arcus Biosciences Inc. (RCUS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 8.4% so far this month. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.95 and a low of $12.95. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $12.95. Year to date ...Dec 1, 2023 · See the latest Arcus Biosciences Inc stock price (RCUS:XNYS), related news, valuation, dividends and more to help you make your investing decisions. Which technical analysis tools can be used to analyze Arcus Biosciences, Inc.? Check out various oscillators, moving averages and other technical indicators ...Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price ...At the time of writing, Arcus Biosciences Inc [RCUS] stock is trading at $16.07, up 6.71%. It is a good measure of the stock's recent performance to check …Shares of Arcus Biosciences ( RCUS 6.71%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news that Gilead ...Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 1,450 shares of the Company’s …Real time Arcus Biosciences (RCUS) stock price quote, stock graph, news & analysis.Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 8.4% so far this month. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.95 and a low of $12.95. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $12.95. Year to date ...Arcus Biosciences-stock Arcus Biosciences Inc Registered Shs Stock , RCUS 14.34 +0.46 +3.35% 01:55:56 PM EDT 11/24/2023 NYSE Add to watchlist 13.88 …2015. 500. Terry Rosen. https://www.arcusbio.com. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer …What happened. Arcus Biosciences, Inc. ( RCUS -5.44%), a clinical-stage oncology company, is up big this morning. Specifically, the drugmaker's shares are up by an astounding 84% as of 10:16 a.m ...Overview Stock Screener Earnings Calendar SectoThe molecules and their uses are investig In the last 3 months, 9 analysts have offered 12-month price targets for Arcus Biosciences. The company has an average price target of $46.33 with a high of $70.00 and a low of $23.00. Below is a ... Track Arcus Biosciences Inc (RCUS) Stock Price, Quot May 9, 2023 · HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT ... The three major U.S. stock exchanges are the New York Stock

In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies.The parties will co-develop Gilead-optioned programs globally and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.Arcus Biosciences saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 6,620,000 shares, an increase of 1.4% from the previous total of 6,530,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a …Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting …25-11-2018 03:42. Juan C. Jaen Purchased 10000 Shares of Arcus Biosciences Inc ... BharataPress. Arcus Biosciences Inc (NYSE:RCUS) President Juan C. Jaen purchased 10,000 shares of the company's stock in a transaction that occurred on Tuesday, November 13th. The stock was bought at an average price of $11.80 per share, with a total value of ...Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price ...

HAYWARD, Calif., January 10, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...13 вер 2023 г. ... ... stock, costing more than $10 million. The very next day, Gilead purchased just over 1 million shares of Arcus Biosciences for nearly $20 million ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Arcus Biosciences, Inc. (NYSE:RCUS) release. Possible cause: Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today. 502%. .

HAYWARD, Calif., January 24, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 3.95% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $19.03 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to date ...

10 hours ago · RTTNews. Dec. 4, 2023, 08:24 AM. (RTTNews) - Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating ... Pohlman covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Seagen, and Genmab. According to TipRanks , Pohlman has an average return of -29.1% and a 18.56% success rate on ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline … In a report released on September 14, Robyn Karnauskas from TArcus Biosciences, Inc. is a clinical-stage biopharmaceutica 10 hours ago · RTTNews. Dec. 4, 2023, 08:24 AM. (RTTNews) - Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating ... Arcus Biosciences stock has received a consens 28 чэр 2023 г. ... ARCUS BIOSCIENCES, INC. (Name of Issuer). Common Stock, par value $0.0001. (Title of Class of Securities). 03969F109. (CUSIP Number). Gilead ...HAYWARD, Calif., January 10, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ... Nov 7, 2023 · Analyst Mara Goldstein of Mizuho SecurShares of Arcus Biosciences (RCUS 3.13%),Evasões 7 vinhos de casta jaen do Dão que vale a Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, ... 2023, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock.Is Arcus Biosciences (NYSE:RCUS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, pricing and company ... Camaraderie, teamwork, integrity. The complexity a Stay up to date on Arcus Biosciences analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here. In a report released yesterday, Mara Goldstein fr[Oct 12, 2023 · Get Arcus Biosciences Inc (RCUS.N)In a report released yesterday, Mara Goldstein from M Arcus Biosciences, Inc. (NYSE:RCUS) today reported financial results for the first ... Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus. That stock purchase agreement was amended and restated in February 2021 in connection with Gilead’s increased equity ...